JW Lifescience Corporation (234080.KS)
- Previous Close
11,900.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 12,680.00 - Volume
0 - Avg. Volume
35,610 - Market Cap (intraday)
185.041B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 500.00 (4.20%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
www.jw-lifescience.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 234080.KS
View MorePerformance Overview: 234080.KS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 234080.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 234080.KS
View MoreValuation Measures
Market Cap
184.27B
Enterprise Value
243.88B
Trailing P/E
4.19
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.83
Price/Book (mrq)
0.92
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
3.17
Financial Highlights
Profitability and Income Statement
Profit Margin
19.77%
Return on Assets (ttm)
7.71%
Return on Equity (ttm)
24.45%
Revenue (ttm)
222.48B
Net Income Avi to Common (ttm)
43.99B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.62B
Total Debt/Equity (mrq)
34.54%
Levered Free Cash Flow (ttm)
5.91B